A Study of MHB009C in Patients With Advanced Solid Tumors

Exclusion Criteria

• •1. History of ≥2 primary malignancies within 5 years prior to informed consent.
• •2. Received chemotherapy within 3 weeks, radiotherapy within 4 weeks, or biologic, endocrine, or immunotherapy within 4 weeks before first study dose.
• •3. Medication of other unmarketed investigational drugs or therapies within 4 weeks before the first dose of investigational drug.
• •4. Brain metastases, bone marrow metastases, leptomeningeal disease, brainstem metastases, or spinal cord compression.
• •5. Severe bone damage caused by bone metastasis of prostate cancer.
• •6. Has adverse reactions from previous anti-tumor treatment that have not recovered to ≤ CTCAE 5.0 Grade 1.
• •7. Severe lung disease affecting pulmonary function.
• •8. Vaccinated within 4 weeks before dosing.
• •9. Active systemic infection requiring treatment within 7 days before dosing.
• •10. Serious cardiovascular or cerebrovascular diseases.
• •11. Uncontrolled third-space effusions not suitable for enrollment.
• •12. Significant bleeding, bleeding tendency, or non-healing wounds within 1 month before first dose.
• •13. Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
• •14. Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.
• •15. Known alcohol or drug dependence.
• •16. Pregnant or breastfeeding women, or individuals planning to conceive. -